Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
Authors:
Open Access
- 6 January 2026
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Abstract
Treatment options for patients with gliomas remain limited, and prognosis is generally poor. While next-generation sequencing (NGS) is increasingly used to stratify glioma patients and guide therapy, its implementation in routine clinical practice remains variable. We conducted a multicenter retrospective study across seven Spanish hospitals to evaluate the clinical utility of NGS in glioma management, focusing on its impact on diagnosis and treatment selection based on the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). A total of 541 glioma patients diagnosed between 2018 and 2022 were included; 76% had glioblastomas and 24% other glioma subtypes. Among glioblastoma patients, 9% harbored ESCAT tier 1/2 alterations and 74% tier 3/4. Molecularly matched therapy was administered in 10.2% of glioblastoma cases. Objective responses were observed in 17.6% of glioblastoma and 33% of non-glioblastoma patients with ESCAT tier 1/2 alterations. Patients with tier 1/2 alterations experienced significantly longer progression-free survival compared to those with tier 3/4. These findings support genomic profiling of gliomas in research centers to expand therapeutic options in molecularly guided clinical trials.Keywords
All Related Versions
Funding Information
- F. Hoffmann-La Roche
This publication has 18 references indexed in Scilit:
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaNew England Journal of Medicine, 2023
- Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysisEuropean Journal of Cancer, 2023
- Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic reviewJournal of Neuro-Oncology, 2023
- Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialThe Lancet Oncology, 2022
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthoodNature Reviews Clinical Oncology, 2020
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Annals of Oncology, 2018
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005